LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

Incyte Corp

Fechado

SetorSaúde

83.94 1.08

Visão Geral

Variação de preço das ações

24h

Atual

Mín

83.13

Máximo

84.48

Indicadores-chave

By Trading Economics

Rendimento

247M

405M

Vendas

163M

1.2B

P/E

Médio do Setor

20.463

35.664

EPS

1.16

Margem de lucro

33.319

Funcionários

2,617

EBITDA

324M

582M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+1.34% upside

Dividendos

By Dow Jones

Próximos Ganhos

28 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

3.3B

17B

Abertura anterior

82.86

Fecho anterior

83.94

Sentimento de Notícias

By Acuity

43%

57%

165 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Incyte Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de set. de 2025, 22:39 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 de set. de 2025, 16:43 UTC

Grandes Movimentos do Mercado

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 de set. de 2025, 16:42 UTC

Grandes Movimentos do Mercado

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 de set. de 2025, 16:35 UTC

Grandes Movimentos do Mercado

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 de set. de 2025, 23:46 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de set. de 2025, 23:46 UTC

Conversa de Mercado

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 de set. de 2025, 23:34 UTC

Conversa de Mercado

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 de set. de 2025, 22:48 UTC

Conversa de Mercado

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 de set. de 2025, 22:12 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL Expects Commercial Launch in 2029

15 de set. de 2025, 22:12 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 de set. de 2025, 22:11 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 de set. de 2025, 22:11 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 de set. de 2025, 22:10 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 de set. de 2025, 21:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 de set. de 2025, 21:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 de set. de 2025, 21:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 de set. de 2025, 21:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 de set. de 2025, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de set. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

15 de set. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

15 de set. de 2025, 19:29 UTC

Conversa de Mercado

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 de set. de 2025, 19:14 UTC

Conversa de Mercado

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 de set. de 2025, 18:16 UTC

Conversa de Mercado

Gold Powers to New High -- Market Talk

15 de set. de 2025, 18:05 UTC

Conversa de Mercado

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 de set. de 2025, 17:50 UTC

Aquisições, Fusões, Aquisições de Empresas

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 de set. de 2025, 17:10 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de set. de 2025, 17:10 UTC

Conversa de Mercado

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 de set. de 2025, 16:52 UTC

Conversa de Mercado

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 de set. de 2025, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

15 de set. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

Comparação entre Pares

Variação de preço

Incyte Corp Previsão

Preço-alvo

By TipRanks

1.34% parte superior

Previsão para 12 meses

Média 84.25 USD  1.34%

Máximo 110 USD

Mínimo 60 USD

Com base em 17 analistas de Wall Street que oferecem metas de preço de 12 meses para Incyte Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

17 ratings

8

Comprar

8

Manter

1

Vender

Pontuação Técnica

By Trading Central

59.52 / 62.66Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

165 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat